🇺🇸 FDA
Pipeline program

AB-101

AB-101-03

Phase 1 small_molecule active

Quick answer

AB-101 for Lupus Nephritis - WHO Class III is a Phase 1 program (small_molecule) at Artiva Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Artiva Biotherapeutics
Indication
Lupus Nephritis - WHO Class III
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials